ArticlesEfficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
Introduction
Long-term treatment of psoriasis with non-biological or biological systemic therapies is often compromised by adverse events, safety and tolerability issues, loss of effect with time, and route of administration (injection vs oral), any of which might contribute to low adherence.1, 2, 3, 4, 5, 6, 7, 8 An effective, well-tolerated, safe, and easy-to-use treatment for psoriasis is needed.
Drug development for psoriasis has targeted signalling between inflammatory cells, such as T cells and myeloid dendritic cells. Biological therapies target specific proinflammatory cytokines, such as tumour necrosis factor α (TNFα), and interleukins 12, 17, and 23.9 Phosphodiesterase 4 is an intracellular enzyme that degrades the secondary messenger cAMP, leading to increased production of proinflammatory cytokines.10, 11, 12, 13, 14, 15, 16 It is the predominant phosphodiesterase expressed in cells of the immune system, including dendritic cells, monocytes, and neutrophils; it is also expressed in keratinocytes. Phosphodiesterase 4 inhibitors are being investigated because they can modulate cAMP concentrations and the related downstream inflammatory signalling cascade.11, 12, 13, 14, 15
Apremilast (CC-10004; Celgene Corporation, Summit, NJ, USA) is a novel, orally available small molecule that specifically inhibits phosphodiesterase 4.12 In vitro, apremilast decreases production of inflammatory mediators such as TNFα, interleukins 2, 12, and 23, and c-x-c motif chemokine 10 by peripheral blood mononuclear cells, and TNFα by natural killer T cells and keratinocytes. In mice with psoriatic xenografts, apremilast reduced epidermal thickness and proliferation and decreased the severity of psoriasiform features.12 The pharmacokinetics of apremilast have been characterised (appendix p 1).17, 18, 19, 20, 21 In a phase 2, randomised, placebo-controlled study, apremilast 20 mg twice daily showed efficacy in patients with moderate to severe plaque psoriasis during 12 weeks of treatment.22 In this dose-ranging study, we assessed the clinical efficacy and safety of apremilast 10, 20, and 30 mg twice daily versus placebo in patients with moderate to severe plaque psoriasis.
Section snippets
Study design and participants
This phase 2b, randomised, multicentre, placebo-controlled, dose-ranging trial was done at 35 sites in the USA and Canada (appendix p 2) between Sept 24, 2008, and Oct 21, 2009. Patients aged 18 years or older were eligible for enrolment if they had had moderate to severe plaque psoriasis (psoriasis area and severity index [PASI] ≥12; body surface area ≥10%) for 6 months or longer and were candidates for phototherapy or systemic therapy. Individuals were excluded if they had a history of, or
Results
88 patients were assigned placebo, 89 apremilast 10 mg, 87 apremilast 20 mg, and 88 apremilast 30 mg (figure 1). Demographic and baseline characteristics were generally well balanced between treatment groups (table 1). Most patients were male, white, and obese (table 1). Patients had plaque psoriasis for a mean of 19 (SD 12) years and 21% had a history of psoriatic arthritis. The mean baseline PASI score was 18·5 and mean baseline body surface area was 22%.
The primary endpoint of PASI-75 at
Discussion
Apremilast, given orally at 20 or 30 mg twice daily, seems to be efficacious, safe, and tolerable for patients with moderate to severe plaque psoriasis. The primary endpoint of PASI-75 at week 16 was achieved by significantly more patients assigned apremilast 20 mg or apremilast 30 mg than placebo, but apremilast 10 mg did not significantly differ from placebo in efficacy. Although no statistical comparisons between apremilast doses were done, apremilast 30 mg had the most favourable outcome
References (28)
- et al.
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
Lancet
(2005) - et al.
Keynote review: phosphodiesterase-4 as a therapeutic target
Drug Discov Today
(2005) - et al.
High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice
Dermatology
(2010) - et al.
A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis
Ann Rheum Dis
(2008) Enbrel [package insert]
(2011)Rheumatrex [package insert]
(2009)- et al.
Adherence to treatment in patients with psoriasis
J Eur Acad Dermatol Venereol
(2006) - et al.
Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis
Arch Dermatol
(2007) - et al.
Tolerability and safety of biological therapies for psoriasis in daily clinical practice: a study of 103 Italian patients
Acta Derm Venereol
(2011) - et al.
Psoriasis
N Engl J Med
(2009)